Depression Risk in Users of Different Doses of Levonorgestrel Intrauterine Systems: a Nationwide Prospective Cohort Study

Overview

Journal Lancet Reg Health Eur

Specialty Health Services

Date 2024 Mar 13

PMID 38476740

Authors

Charlotte Wessel Skovlund

Amalie Lykkemark Moller

Christian Torp-Pedersen

Lina Steinrud Morch

Amani Meaidi

Affiliations

Soon will be listed here.

Abstract

Background: Use of the high-dose levonorgestrel-releasing intrauterine system (LNG-IUS) has been associated with increased risk of incident depression. Evidence is lacking on the influence of use of two recently marketed low-dose LNG-IUS on risk of depression. This study aims to examine associations between use of different doses of LNG-IUS and risk of depression.

Methods: We conducted a nationwide prospective cohort study involving all first-time users of an LNG-IUS among all Danish nulliparous women aged 15-34 years with no medical history of depression, major psychiatric diseases, endometriosis, heavy menstrual bleeding, polyp, myoma, dysmenorrhoea, iron supplement use, abortion, and infertility treatment.

Findings: A total of 46,565 first-time users of LNG-IUS were followed for 80,516 person-years with 1,531 incident initiations of antidepressant use observed during follow-up. Use of the high-dose LNG-IUS containing 52 mg levonorgestrel was initiated by 9,902 (21%) women, while 20,665 (44%), and 15,998 (34%) initiated use of the low-dose LNG-IUS containing 19·5 mg and 13·5 mg levonorgestrel, respectively.The age-, calendar-time-, and education-standardised incidence rates of first-time depression per 1,000 person-years at full LNG-IUS duration were 30.8 (95% CI 23·6-39·5) for the 52 mg LNG-IUS, 19·8 (95% CI 16·1; 24·0) for the 19·5 mg LNG-IUS, and 17·7 (95% CI 14·4-21·5) for the 13·5 mg LNG-IUS-. Compared to the high-dose 52 mg LNG-IUS, the adjusted number of avoided depressions per 1,000 person-years were 11·0 (95% CI 7·1-14·9) for the 19·5 mg LNG-IUS and 13·1 (95% CI 9·6-16·6) for the 13·5 mg LNG-IUS. The corresponding adjusted rate ratios were 0·77 (95% CI 0·68; 0·88) and 0·85 (95% CI 0·75-0·96). The reduced risk of depression with low-dose LNG-IUS compared to high-dose LNG-IUS was observable throughout duration of use.

Interpretation: Use of low-dose LNG-IUS containing 19·5 mg and 13·5 mg levonorgestrel, respectively, were associated with a reduced risk of incident depression compared to use of the high-dose 52 mg LNG-IUS. The study suggests that low-dose LNG-IUS should be preferred over the high-dose LNG-IUS for contraceptive purpose.

Funding: Sygeforsikringen "Danmark" grant: 2021-0128.

References

Pasvol T, MacGregor E, Rait G, Horsfall L . Time trends in contraceptive prescribing in UK primary care 2000-2018: a repeated cross-sectional study. BMJ Sex Reprod Health. 2021; 48(3):193-198. PMC: 9279840. DOI: 10.1136/bmjsrh-2021-201260. View

Frokjaer V, Pinborg A, Holst K, Overgaard A, Henningsson S, Heede M . Role of Serotonin Transporter Changes in Depressive Responses to Sex-Steroid Hormone Manipulation: A Positron Emission Tomography Study. Biol Psychiatry. 2015; 78(8):534-43. DOI: 10.1016/j.biopsych.2015.04.015. View

Knudsen L, Olsen J . The Danish Medical Birth Registry. Dan Med Bull. 1998; 45(3):320-3. View

Rademacher K, Sripipatana T, Pfitzer A, Mackay A, Thurston S, Jackson A . A Global Learning Agenda for the Levonorgestrel Intrauterine System (LNG IUS): Addressing Challenges and Opportunities to Increase Access. Glob Health Sci Pract. 2018; 6(4):635-643. PMC: 6370355. DOI: 10.9745/GHSP-D-18-00383. View

Skovlund C, Morch L, Kessing L, Lidegaard O . Association of Hormonal Contraception With Depression. JAMA Psychiatry. 2016; 73(11):1154-1162. DOI: 10.1001/jamapsychiatry.2016.2387. View

Seeber B, Ziehr S, GschlieBer A, Gschliesser A, Moser C, Mattle V . Quantitative levonorgestrel plasma level measurements in patients with regular and prolonged use of the levonorgestrel-releasing intrauterine system. Contraception. 2012; 86(4):345-9. DOI: 10.1016/j.contraception.2012.01.015. View

Gemzell-Danielsson K, Schellschmidt I, Apter D . A randomized, phase II study describing the efficacy, bleeding profile, and safety of two low-dose levonorgestrel-releasing intrauterine contraceptive systems and Mirena. Fertil Steril. 2012; 97(3):616-22.e1-3. DOI: 10.1016/j.fertnstert.2011.12.003. View

Lindh I, Skjeldestad F, Gemzell-Danielsson K, Heikinheimo O, Hognert H, Milsom I . Contraceptive use in the Nordic countries. Acta Obstet Gynecol Scand. 2016; 96(1):19-28. DOI: 10.1111/aogs.13055. View

King L, Michels K, Graubard B, Trabert B . Trends in oral contraceptive and intrauterine device use among reproductive-aged women in the US from 1999 to 2017. Cancer Causes Control. 2021; 32(6):587-595. PMC: 8096680. DOI: 10.1007/s10552-021-01410-8. View

10.

Skovlund C, Morch L, Kessing L, Lange T, Lidegaard O . Association of Hormonal Contraception With Suicide Attempts and Suicides. Am J Psychiatry. 2017; 175(4):336-342. DOI: 10.1176/appi.ajp.2017.17060616. View

11.

Lundin C, Wikman A, Lampa E, Bixo M, Gemzell-Danielsson K, Wikman P . There is no association between combined oral hormonal contraceptives and depression: a Swedish register-based cohort study. BJOG. 2021; 129(6):917-925. DOI: 10.1111/1471-0528.17028. View

12.

Meaidi A, Torp-Pedersen C, Lidegaard O, Morch L . Ectopic Pregnancy Risk in Users of Levonorgestrel-Releasing Intrauterine Systems With 52, 19.5, and 13.5 mg of Hormone. JAMA. 2023; 329(11):935-937. PMC: 10031393. DOI: 10.1001/jama.2023.0380. View

13.

Munk-Jorgensen P, Mortensen P . The Danish Psychiatric Central Register. Dan Med Bull. 1997; 44(1):82-4. View

14.

Elsayed M, Dardeer K, Khehra N, Padda I, Graf H, Soliman A . The potential association between psychiatric symptoms and the use of levonorgestrel intrauterine devices (LNG-IUDs): A systematic review. World J Biol Psychiatry. 2022; 24(6):457-475. DOI: 10.1080/15622975.2022.2145354. View

15.

Hognert H, Skjeldestad F, Gemzell-Danielsson K, Heikinheimo O, Milsom I, Lidegaard O . Ecological study on the use of hormonal contraception, abortions and births among teenagers in the Nordic countries. BMJ Open. 2018; 8(10):e022473. PMC: 6224744. DOI: 10.1136/bmjopen-2018-022473. View

16.

Lynge E, Sandegaard J, Rebolj M . The Danish National Patient Register. Scand J Public Health. 2011; 39(7 Suppl):30-3. DOI: 10.1177/1403494811401482. View

17.

Roland N, Baricault B, Weill A, Bouillon K, Dray-Spira R, Duranteau L . Association Between Doses of Levonorgestrel Intrauterine Systems and Subsequent Use of Psychotropic Drugs in France. JAMA. 2022; 329(3):257-259. PMC: 9857179. DOI: 10.1001/jama.2022.21471. View

18.

Wallach Kildemoes H, Sorensen H, Hallas J . The Danish National Prescription Registry. Scand J Public Health. 2011; 39(7 Suppl):38-41. DOI: 10.1177/1403494810394717. View

19.

Smith K, Nayyar S, Rana T, Archibong A, Looney K, Nayyar T . Do Progestin-Only Contraceptives Contribute to the Risk of Developing Depression as Implied by Beta-Arrestin 1 Levels in Leukocytes? A Pilot Study. Int J Environ Res Public Health. 2018; 15(9). PMC: 6163405. DOI: 10.3390/ijerph15091966. View